# Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

> **NCT04592380** · PHASE3 · WITHDRAWN · sponsor: **The Medicines Company**

## Conditions studied

- Dyspnea
- Hypertension
- Acute Heart Failure

## Interventions

- **DRUG:** Stage 1: Clevidipine (double-blinded)
- **DRUG:** Stage 1: Placebo (double-blinded)
- **DRUG:** Stage 2: Clevidipine (open-label)
- **DRUG:** Stage 2: Standard of Care (open-label)

## Key facts

- **NCT ID:** NCT04592380
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-08
- **Primary completion:** 2016-02
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Product was divested to Chiesi USA, who decided to not move forward with study.
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592380, "Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04592380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*